HomeInvesting NewsPatent dispute over Gilead's HIV and HBV medications resolved with many generic...

Patent dispute over Gilead’s HIV and HBV medications resolved with many generic drugmakers

Published on

Gilead Sciences (NASDAQ:GILD)

On Monday, Gilead Sciences (NASDAQ:GILD), a pharmaceutical company based in the United States, announced the conclusion of patent litigation and other disputes with various generic pharmaceutical firms over its HIV medications Descovy and Odefsey and its Vemlidy treatment for hepatitis B virus.

GILD disclosed the settlements in a regulatory filing, and the parties involved included Canada’s Apotex and India’s Lupin, Macleods Pharma, Hetero Labs, and Cipla.

The patents on tenofovir alafenamide covering Descovy and Vemlidy run out on October 31, 2031, while Odefsey’s run out on January 31, 2032; the agreements provide the generic drugmakers a non-exclusive license to use those patents in the United States.

After 2031 and 2032, generic drugmakers will be able to produce their own versions of the HIV and HBV medications, but until then, Gilead (GILD) will have a monopoly on the market.

RBC Capital Markets research analyst Brian Abrahams wrote in a short research note, “We regard (the settlements) as a big positive for the HIV franchise longevity the $3B in sales these medicines produce, and see the potential for stock gain on today’s news.”

As the market opened, GILD shares were up $4.30, or 4.3%, to $68.10.

Gilead Sciences (NASDAQ:GILD) recently revealed that its antibody-drug combination Trodelvy demonstrated a statistically significant and clinically relevant increase of 3.2 months in overall survival (OS) over chemotherapy in specific patients with HR+/HER2- metastatic breast cancer.

The data come from the Phase 3 TROPiCS-02 study, in which 543 patients were randomly assigned to receive either Trodelvy or the investigators’ preferred treatment. All of the participants in this study had received prior endocrine therapy and at least two prior chemotherapies for metastatic illness.

The trial’s secondary goal, overall survival, showed that patients in the Trodelvy arm had a median OS of 14.4 months, compared to 11.2 months in the comparison arm. This translated to a 3.2-month advantage against those in the TPC arm.

Another important secondary goal, objective response rate (ORR), showed statistically significant improvement in favor of Trodelvy compared to TPC in this experiment.

The safety profile of Trodelvy in TROPiCS-02 was similar to earlier trials for the medication, GILD stated, adding that there were no new safety flags.

Featured Image – Megapixl © Ukrphoto

See Disclaimer Please

Latest News

Recent Surge in Tesla Stock: Exactly What Caused It?

Tesla Stock (NASDAQ:TSLA) As of 11:30 a.m ET on Friday, Tesla stock was up 2.3%...

Here’s Why Carvana Stock Fell Quite So Much as 23.7% This Week

Carvana Stock (NYSE:CVNA) According to data provided by S&P Global Market Intelligence, Carvana stock fell...

Here’s Why Tellurian Stock Is Rising Again Today

Tellurian Stock (NYSEMKT:TELL) Tellurian stock was up 6.5% as of 11:06 p.m. ET today after...

Is It Time to Buy Chewy Stock?

Chewy Stock (NYSE:CHWY) Pet supplies are one of the few consumer goods that do well,...

More like this

2 Casino Stocks You Should Consider

With a recession on the horizon, investors must be more selective than ever. Analysts...

(Exxon Mobil Stock) Exxon Ceo Warns Biden Administration Against Restricting Fuel Exports

Exxon (Exxon Mobil Stock) opposes calls for oil corporations to reduce international exports and...

Apple Stock Loses $120 Billion Because of a Rare Downgrade

Apple stock just took a significant knock after it was once considered to be...

Meta Stock Tops Morningstar List of the Most Undervalued Stocks 

Morningstar compiled a list of the most undervalued stocks among those with a large...

Hd Stock up as Foundation to Contribute Up to $1 Million to Aid Communities Affected by Hurricane Ian

HD stock was trading at $280.23 as of 12:55 PM EDT. The Home Depot Foundation...

Making the Cut: Micron (Micron Stock)

Micron Technology Inc (Micron Stock) latest outlook brings expectations back to normal, although the...